Wegovy Oral Pill

The Wegovy pill is an oral, once-daily tablet containing semaglutide, the same clinically proven active ingredient found in Wegovy injections. A needle-free alternative for adults with obesity or weight-related health conditions, it works by mimicking a natural hormone that reduces appetite and helps you feel fuller for longer.

1. Appetite Control Semaglutide acts on appetite receptors in the brain to help you feel satisfied with smaller portions and experience fewer cravings throughout the day.
2. Blood Sugar Regulation The Wegovy pill stimulates insulin secretion in response to rising blood glucose levels, helping to prevent spikes in blood sugar that can trigger hunger and cravings.
3. Slows Gastric Emptying By slowing the rate at which food moves from the stomach to the intestines, the pill helps you feel fuller for longer after meals, reducing the likelihood of overeating.

Unlike the Wegovy injection, which is absorbed directly into the bloodstream from under the skin, the oral tablet must pass through the digestive system. Because only a small amount reaches the bloodstream via this route, the pill uses SNAC technology and is taken at a higher concentration. This makes correct dosing and administration essential for it to work effectively.

The Wegovy pill is one of the most clinically supported weight loss treatments available. Adults may be eligible if they have:

• A BMI of 30 or higher
• A BMI of 27 or higher with related conditions such as high blood pressure or type 2 diabetes

Note: You must consult a doctor and obtain a prescription. Speak with Farmeci experts for guidance.

Treatment begins at a lower dose and gradually increases to minimise side effects.

Daily Dose Days 1–30 (Month 1): 1.5 mg once daily

Days 31–60 (Month 2): 4 mg once daily

Days 61–90 (Month 3): 9 mg once daily

Day 91 onwards (Maintenance): 25 mg once daily

Note: Always consult your doctor to determine the correct dosage based on your health goals. The full treatment effect is typically seen at the maintenance dose of 25mg.

Clinical trial data demonstrates that the Wegovy pill produces meaningful, sustained weight loss when taken correctly alongside a reduced-calorie diet and increased physical activity.

OASIS 1 Clinical Trial: In the OASIS 1 Phase 3 clinical trial, participants taking 50mg semaglutide lost an average of 15.1% of their body weight over 68 weeks, compared to 2.4% in the placebo group.

OASIS 4 Clinical Trial: In the OASIS 4 trial, participants taking 25mg of oral semaglutide daily for 64 weeks lost an average of 16.6% of their body weight. Approximately one in three participants achieved 20% or more body weight loss.

Key findings from the OASIS 1 trial:

• Average weight loss of 15.1% vs 2.4% with placebo
• Highly dependent on correct and consistent daily administration
• Results improve with maintained lifestyle changes

1. Take one Wegovy tablet first thing in the morning on a completely empty stomach, with no more than 120ml of plain water.
2. Wait at least 30 minutes before eating any food, drinking any beverages, or taking any other oral medications.
3. Swallow the tablet whole. Do not crush, cut, chew, or dissolve it.

• Do not take more than one Wegovy pill per day.
• Do not take with any liquid other than water.
• Do not take alongside any other semaglutide-containing products or other GLP-1 receptor agonists.
• Do not share your medication with others.
• Do not store tablets outside of their original closed bottle.

If you miss a day, skip the missed dose entirely. Do not double up the following day. Simply resume your regular schedule.

Both the Wegovy pill and the Wegovy injection contain semaglutide and work by activating GLP-1 receptors to reduce appetite and increase feelings of fullness. However, there are important differences in how they are taken, how they are absorbed, and their average weight loss outcomes.

The Wegovy pill is taken as a once-daily oral tablet, while the injection is administered once weekly. The pill is available in four strengths (1.5mg, 4mg, 9mg, and 25mg), whereas the injection comes in a wider range including the recently approved 7.2mg dose.

in terms of weight loss, the pill produced an average of 15.1% body weight reduction at 68 weeks in the OASIS 1 trial, compared to 20.7% at 72 weeks in the STEP UP trial for the injection. The pill can be stored at room temperature between 20°C and 25°C, while Wegovy injectable pens must be kept refrigerated at 2°C–8°C. The pill is needle-free; the injection is not.

The Wegovy injection may be better suited to those who prefer the convenience of once-weekly dosing and benefit from more consistent, predictable absorption into the bloodstream. Clinical data suggests it produces slightly greater average weight loss than the oral tablet.

The Wegovy pill may be preferable for those who are averse to needles, find a daily tablet routine easier to maintain, or prefer not to manage refrigerated storage.

Suitability depends on your individual preference, medical history, and clinical assessment. Always speak with a pharmacist or prescriber before switching or starting any new treatment.

Common (Usually Mild):

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Stomach (abdominal) pain
• Heartburn or indigestion
• Bloating or belching
• Headache
• Fatigue
• Dizziness

Less Common:

• Dizziness
• Fatigue

Rare but Serious:

• Pancreatitis
• Gallbladder problems
• Severe allergic reactions

Seek medical attention immediately if you experience severe symptoms.

Unlike the Wegovy injection, which must be kept refrigerated at 2°C–8°C, the Wegovy pill is stored at room temperature, making it easier to manage at home or while travelling.

• Store at room temperature between 20°C and 25°C (68°F–77°F)
• Store in a dry place away from moisture
• Keep in the original child-resistant bottle with the cap tightly closed
• Do not transfer tablets to any other container
• Keep out of reach of children

Do not take the Wegovy pill if you:

• Have a personal or family history of medullary thyroid carcinoma (MTC)
• Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Have had a serious allergic reaction to semaglutide or any ingredient in Wegovy
• Are pregnant, planning to become pregnant, or breastfeeding
• Are currently taking another semaglutide-containing product or other GLP-1 receptor agonist

Always inform your prescriber of your full medical history and all medications before starting treatment.

If the Wegovy pill is not suitable for you, your doctor may recommend:

• Wegovy injectable pens (semaglutide) — clinically proven to support an average of 20.7% body weight loss at 72 weeks (STEP UP trial)
• Mounjaro (tirzepatide) — highly effective and widely used in the UK

Note: Mounjaro is considered the most effective alternative for weight loss.

If you are currently taking Wegovy injections or Mounjaro and are considering switching to the Wegovy pill, the tables below provide indicative dose guidance. These are starting-point estimates only your actual dose will be determined by a clinician based on a full review of your medical history, tolerability, and individual circumstances.